z33 peptideANDREW D. HUBERMAN: Before we start, I might like to emphasise this podcast is different from my training and research roles at Stanford.ANDREW D. HUBERMAN: But preserve in mind that CJC1295 has entered medical trials. There was a Dying within one of many scientific trials that was related to cardiovascular dysfunction.ANDREW D. HUBERMAN